BLAINJECTIONINJECTABLE
Approved
Nov 2019
Lifecycle
Peak
Competitive Pressure
30/100
Mechanism of Action
TNF-alpha and block its interaction with the p55 and p75 cell surface TNF receptors. Adalimumab products also lyse surface TNF expressing cells in vitro in the presence of complement. Adalimumab products do not bind or inactivate lymphotoxin (TNF-beta). TNF is a naturally occurring cytokine that is…
Indications (13)
moderately to severely active Crohn's disease in adultsoldermoderately to severely active ulcerative colitis in adult patientsphototherapyother systemic therapies are medically less appropriatemoderate to severe hidradenitis suppurativa in adult patientsnon-infectious intermediateposteriorpanuveitis in adult patientsrheumatoid arthritisCrohn's diseaseulcerative colitispsoriasis